https://doi.org/10.1172/JCI196648 In this Research Article, Styliani Karanika & team report on an intranasal DNA vaccine that accelerates TB cure and achieves better outcomes than standard or drug-resistant regimens alone in preclinical models.
The figure shows mouse lungs with therapeutic intranasal Mip3a/relMt b fusion immunization, revealing local dendritic cell infiltration and enhanced colocalization with T cells.
1Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
2W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
3Division of Hematological Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital, Baltimore, Maryland, USA.